Jones Hill Capital LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Jones Hill Capital LP reported 29 stock positions worth $470.4 million. Its top holding was Biomarin Pharmaceutical (BMRN) at 17.4% of the portfolio, followed by Gilead Sciences (GILD, 9.2%) and Arcutis Biotherapeutics (ARQT, 6.1%). Compared with Q1 2026, it opened 15 new positions, sold out of 12, added to 5 and reduced 9. The biggest buy was a new position in Gilead Sciences (GILD) and the biggest sale Vertex Pharmaceuticals (VRTX, shares −90%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002102314
- Portfolio Value
- $470.4M (Q2 2026)
- SEC Filing
- 0002102314-26-000005 ↗ filed Aug 13, 2026
Holdings Value
Holdings 29 stocks · $470.4M
| BMRN Biomarin Pharmaceutical Inc. | 17.42% | 1,431,590 | $81.9M | Add +12.9% |
| GILD Gilead Sciences Inc. | 9.21% | 343,043 | $43.3M | New |
| ARQT Arcutis Biotherapeutics Inc. | 6.07% | 1,089,701 | $28.6M | New |
| MDGL Madrigal Pharmaceuticals Inc. | 6.00% | 52,545 | $28.2M | New |
| BCAX Bicara Therapeutics Inc. | 5.63% | 892,621 | $26.5M | Reduce -29.2% |
| RLMD Relmada Therapeutics Inc. | 5.38% | 3,655,075 | $25.3M | Add +966.4% |
| TRVI Trevi Therapeutics Inc. | 5.31% | 1,339,212 | $25.0M | Add +261.8% |
| PHVS Pharvaris NV | 4.98% | 677,879 | $23.4M | Add +305.9% |
| XENE Xenon Pharmaceuticals Inc. | 4.72% | 367,900 | $22.2M | New |
| ANIP Ani Pharmaceuticals Inc. | 4.11% | 233,808 | $19.4M | Reduce -26.6% |
| IMCR Immunocore Holdings PLC-ADR | 3.46% | 512,856 | $16.3M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 3.41% | 894,058 | $16.1M | Reduce -44.1% |
| INSM Insmed Inc. | 2.77% | 122,375 | $13.0M | New |
| NUVL Nuvalent Inc. Class A | 2.58% | 98,442 | $12.2M | Reduce -67.3% |
| CAPR Capricor Therapeutics Inc. | 2.15% | 420,751 | $10.1M | Reduce -53.7% |
| ACRS Aclaris Therapeutics Inc. | 1.98% | 1,759,492 | $9.3M | New |
| IMUX Immunic Inc. | 1.76% | 539,814 | $8.3M | New |
| ORIC Oric Pharmaceuticals Inc. | 1.72% | 747,313 | $8.1M | New |
| TNXP Tonix Pharmaceuticals Holdin | 1.70% | 625,428 | $8.0M | Add +38.3% |
| SNDX Syndax Pharmaceuticals Inc. | 1.58% | 340,000 | $7.4M | New |
| OLMA Olema Pharmaceuticals Inc. | 1.53% | 574,166 | $7.2M | New |
| VIR Vir Biotechnology Inc. | 1.43% | 659,213 | $6.7M | Reduce -45.0% |
| CRBP Corbus Pharmaceuticals Holdi | 1.30% | 653,572 | $6.1M | New |
| DNTH Dianthus Therapeutics Inc. | 1.18% | 57,100 | $5.6M | New |
| VRTX Vertex Pharmaceuticals Inc. | 1.17% | 11,123 | $5.5M | Reduce -89.8% |
| ELVN Enliven Therapeutics Inc. | 0.54% | 49,850 | $2.5M | Reduce -91.6% |
| GPCR Structure Therapeutics Inc. | 0.46% | 40,567 | $2.2M | Reduce -59.7% |
| PHAT Phathom Pharmaceuticals Inc. | 0.37% | 161,486 | $1.8M | New |
| ACHV Achieve Life Sciences Inc. | 0.04% | 26,760 | $175K | New |
Portfolio Sells Q1 2026 → Q2 2026
| VRTX Vertex Pharmaceuticals Inc. | Reduce -89.8% | 1.17% | −9.22 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −8.03 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −5.89 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −5.23 |
| ELVN Enliven Therapeutics Inc. | Reduce -91.6% | 0.54% | −4.45 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −4.07 |
| NUVL Nuvalent Inc. Class A | Reduce -67.3% | 2.58% | −4.02 |
| CAPR Capricor Therapeutics Inc. | Reduce -53.7% | 2.15% | −3.77 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −2.91 |
| NUVB Nuvation Bio Inc. | Sold out | 0.00% | −2.19 |
| ORKA Oruka Therapeutics Inc. | Sold out | 0.00% | −1.48 |
| CTNM Contineum Therapeutics Inc. Class A | Sold out | 0.00% | −1.44 |
| MANE Veradermics Inc. | Sold out | 0.00% | −1.37 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -44.1% | 3.41% | −1.35 |
| ANIP Ani Pharmaceuticals Inc. | Reduce -26.6% | 4.11% | −1.14 |
| TRDA Entrada Therapeutics Inc. | Sold out | 0.00% | −1.01 |
| VIR Vir Biotechnology Inc. | Reduce -45.0% | 1.43% | −0.87 |
| GPCR Structure Therapeutics Inc. | Reduce -59.7% | 0.46% | −0.58 |
| SLN Silence Therapeutics PLC-ADR | Sold out | 0.00% | −0.34 |
| AVBP Arrivent Biopharma Inc. | Sold out | 0.00% | −0.23 |
| BCAX Bicara Therapeutics Inc. | Reduce -29.2% | 5.63% | +0.26 |
Portfolio Buys Q1 2026 → Q2 2026
| GILD Gilead Sciences Inc. | New | 9.21% | +9.21 |
| ARQT Arcutis Biotherapeutics Inc. | New | 6.07% | +6.07 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 6.00% | +6.00 |
| RLMD Relmada Therapeutics Inc. | Add +966.4% | 5.38% | +4.87 |
| XENE Xenon Pharmaceuticals Inc. | New | 4.72% | +4.72 |
| TRVI Trevi Therapeutics Inc. | Add +261.8% | 5.31% | +4.36 |
| PHVS Pharvaris NV | Add +305.9% | 4.98% | +3.97 |
| IMCR Immunocore Holdings PLC-ADR | New | 3.46% | +3.46 |
| INSM Insmed Inc. | New | 2.77% | +2.77 |
| BMRN Biomarin Pharmaceutical Inc. | Add +12.9% | 17.42% | +2.06 |
| ACRS Aclaris Therapeutics Inc. | New | 1.98% | +1.98 |
| IMUX Immunic Inc. | New | 1.76% | +1.76 |
| ORIC Oric Pharmaceuticals Inc. | New | 1.72% | +1.72 |
| SNDX Syndax Pharmaceuticals Inc. | New | 1.58% | +1.58 |
| OLMA Olema Pharmaceuticals Inc. | New | 1.53% | +1.53 |
| CRBP Corbus Pharmaceuticals Holdi | New | 1.30% | +1.30 |
| DNTH Dianthus Therapeutics Inc. | New | 1.18% | +1.18 |
| PHAT Phathom Pharmaceuticals Inc. | New | 0.37% | +0.37 |
| TNXP Tonix Pharmaceuticals Holdin | Add +38.3% | 1.70% | +0.36 |
| ACHV Achieve Life Sciences Inc. | New | 0.04% | +0.04 |